AbbVie Inc. (ABBV)
Stock Price Chart
Key Info
| Market Cap | 170.79B |
| Revenue (ttm) | 34.06B |
| Net Income (ttm) | 8.44B |
| Shares Out | 1.76B |
| EPS (ttm) | 5.65 |
| PE Ratio | 17.15 |
| Forward PE | 10.14 |
| Dividend | $4.72 |
| Dividend Yield | 4.87% |
Stock Quote
| Trading Day | Jul 10, 2020 |
| Last Price | $96.91 |
| Previous Close | $97.94 |
| Change ($) | -1.03 |
| Change (%) | -1.05% |
| Day's Open | 98.06 |
| Day's Range | 96.40 - 98.33 |
| Day's Volume | 1,818,351 |
| 52-Week Range | 62.55 - 100.69 |
More Stats
| Market Cap | 170.79B |
| Enterprise Value | 196.69B |
| Earnings Date (est) | Jul 31, 2020 |
| Ex-Dividend Date | Apr 14, 2020 |
| Shares Outstanding | 1.76B |
| Float | 1.47B |
| EPS (basic) | 5.67 |
| EPS (diluted) | 5.65 |
| FCF / Share | 9.15 |
| Dividend | $4.72 |
| Dividend Yield | 4.87% |
| Earnings Yield | 5.83% |
| FCF Yield | 7.93% |
| Payout Ratio | 77.40% |
| Shares Short | 19.76M |
| Short Ratio | 1.94 |
| Short % of Float | 1.12% |
| Beta | 0.82 |
| PE Ratio | 17.15 |
| Forward PE | 10.14 |
| P/FCF Ratio | 12.60 |
| PS Ratio | 5.01 |
| PB Ratio | n/a |
| Revenue | 34.06B |
| Operating Income | 13.58B |
| Net Income | 8.44B |
| Free Cash Flow | 13.55B |
| Net Cash | -25.90B |
| Net Cash / Share | -14.70 |
| Gross Margin | 75.83% |
| Operating Margin | 39.86% |
| Profit Margin | 24.80% |
| FCF Margin | 39.79% |
| ROA | 11.80% |
| ROE | n/a |
| ROIC | 20.70% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33,266 | 32,753 | 28,216 | 25,638 | 22,859 | 19,960 | 18,790 | 18,380 | 17,444 | 15,638 |
| Revenue Growth | 1.57% | 16.08% | 10.06% | 12.16% | 14.52% | 6.23% | 2.23% | 5.37% | 11.55% | - |
| Gross Profit | 25,827 | 25,035 | 21,174 | 19,806 | 18,359 | 15,534 | 14,209 | 13,872 | 12,805 | 11,345 |
| Operating Income | 12,983 | 6,383 | 9,545 | 9,340 | 7,537 | 3,411 | 5,664 | 5,817 | 3,620 | 4,717 |
| Net Income | 7,882 | 5,687 | 5,309 | 5,953 | 5,144 | 1,774 | 4,128 | 5,275 | 3,433 | 4,178 |
| Shares Outstanding | 1,481 | 1,541 | 1,596 | 1,622 | 1,625 | 1,595 | 1,589 | 1,577 | 1,577 | - |
| Earnings Per Share | 5.28 | 3.66 | 3.30 | 3.63 | 3.13 | 1.10 | 2.56 | 3.35 | 2.18 | 2.65 |
| EPS Growth | 44.26% | 10.91% | -9.09% | 15.97% | 184.55% | -57.03% | -23.58% | 53.67% | -17.74% | - |
| Dividend Per Share | 4.28 | 3.59 | 2.56 | 2.28 | 2.02 | 1.66 | 1.60 | - | - | - |
| Dividend Growth | 19.22% | 40.23% | 12.28% | 12.87% | 21.69% | 3.75% | - | - | - | - |
| Operating Cash Flow | 13,324 | 13,427 | 9,960 | 7,041 | 7,535 | 3,549 | 6,267 | 6,345 | 6,247 | 4,976 |
| Capital Expenditures | -552 | -638 | -529 | -479 | -532 | -612 | -491 | -333 | -356 | -448 |
| Free Cash Flow | 12,772 | 12,789 | 9,431 | 6,562 | 7,003 | 2,937 | 5,776 | 6,012 | 5,891 | 4,528 |
| Cash & Equivalents | 39,924 | 8,061 | 9,789 | 6,423 | 8,407 | 8,374 | 9,895 | 7,976 | 653 | 1,883 |
| Total Debt | 66,728 | 40,310 | 37,368 | 36,842 | 31,671 | 14,977 | 14,723 | 15,672 | 48.00 | - |
| Net Cash / Debt | -26,804 | -32,249 | -27,579 | -30,419 | -23,264 | -6,603 | -4,828 | -7,696 | 605 | 1,883 |
| Assets | 89,115 | 59,352 | 70,786 | 66,099 | 53,050 | 27,513 | 29,198 | 27,008 | 19,521 | 21,135 |
| Liabilities | 97,287 | 67,798 | 65,689 | 61,463 | 49,105 | 25,771 | 24,706 | 23,645 | 7,589 | 5,432 |
| Book Value | -8,172 | -8,446 | 5,097 | 4,636 | 3,945 | 1,742 | 4,492 | 3,363 | 11,932 | 15,703 |
Company Profile
Company Details
| Full Name | AbbVie Inc. |
| Country | United States |
| Employees | 30,000 |
| CEO | Richard A. Gonzalez |
Stock Information
| Ticker Symbol | ABBV |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | NYSE: ABBV |
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.